OPPI Calls for Predictable Drug Policies and Selective Use of Price Controls in India
The Organisation of Pharmaceutical Producers of India (OPPI) highlights the need for consistent policies to improve drug approvals and clinical trials in India, emphasizing innovation beyond generic manufacturing. OPPI's Director General, Anil Matai, warns that frequent use of Para 19 of the Drug Price Control Order, which allows government price cuts on medicines, could harm industry sentiment, deter investments, and affect healthcare services. He advocates for selective use of pricing controls to maintain market stability and support pharmaceutical growth.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (46/100). Lens Score 47/100.
Outlets measured: economictimes, thefinancialexpress, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (35–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 18 Nov, 12:46 pm. Other outlets followed.
